Advanced Bio Healing

Site navigation

Navigation

Press Releases

Advanced BioHealing to Present at AdvaMed 2009: The MedTech Conference


Westport, CT – October 12, 2009 – Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that Senior Vice President Dean Tozer will present at AdvaMed 2009: The MedTech Conference. The conference will be held October 12-14, 2009, at the Walter E. Washington Convention Center in Washington, D.C. Mr. Tozer will deliver his presentation on behalf of ABH on Wednesday, October 14, 2009, at 10:40 a.m. in Room 304.

In his presentation, Mr. Tozer will highlight the Company’s recently announced strategic growth plan to expand sales of its lead product, Dermagraft®, extend its product use to multiple indications, and diversify its product portfolio. By year-end 2009, ABH is projected to grow to $80 million in revenue and over 260 employees.

“We are delighted to have been selected to present at AdvaMed 2009,” said Mr. Tozer. “By successfully commercializing a regenerative medicine product, we have done what many thought was impossible. Now, having proven the viability of our technology and developed a performance-driven culture where employees believe in the mission of ABH, we’ve set our sights on new growth initiatives and opportunities to extend the positive impact that regenerative medicine can have on healthcare. I look forward to sharing the ABH commercialization success story and future plans with AdvaMed attendees.”

Applications for the company profile presentations at AdvaMed 2009 were evaluated by a committee of industry leaders and stakeholders; approximately 45 companies with the highest scores were offered the opportunity to present.

About Advanced BioHealing, Inc.
Advanced BioHealing develops and commercializes living cell technologies that repair damaged human tissue and enable the body to heal itself. A privately held company with more than 200 employees, Advanced BioHealing maintains corporate offices in Westport, CT and a 70,000 sq. ft. manufacturing facility in La Jolla, CA. To meet Advanced BioHealing’s executives and learn more about the Company, please visit the Company’s web site at www.ABH.com.

About Dermagraft®
Dermagraft is a bio-engineered skin substitute that repairs tissue damaged by disease or injury and supports the body’s natural healing process. It is currently FDA approved to treat diabetic foot ulcers. More than 150,000 applications of Dermagraft have been administered in over 1,000 wound care centers and outpatient clinics nationwide. For videos of Dermagraft in action, case studies, research and more, visit www.Dermagraft.com.

About Diabetic Foot Ulcers
In 2007, 23.6 million people, or 7.8% of the American population, had diabetes. Referred to as the “epidemic of our time” by the U.S. Centers for Disease Control and Prevention, incidence of diabetes is expected to increase 165% by 2050. The World Health Organization estimates 171 million people have diabetes globally and that number is expected to double by 2030. As a chronic medical condition among many diabetes patients, it is estimated that 15-25% will develop a foot ulcer in their lifetime, putting them at a 14-24% risk for lower limb amputation, and a 45% chance of death within 5 years if not managed properly. Also generating a significant financial impact, each new incidence of diabetic foot ulcers (DFU) in the U.S. costs nearly $40,000 to treat in the first two years. In the U.S. and Europe combined, DFU incidence is estimated to be between 1.7 to 2.5 million annually. Risk of death from unhealed neuropathic ulcers like DFUs is greater than both breast cancer and prostate cancer combined.

Media Contacts:

  • Lindsey Hart
    • Advanced BioHealing
    • lhart@abh.com
    • Direct: (773) 697-3838
    • Cell: (206) 335-0114
  • Kristy DelMuto